International Conference on Systemics, Cybernetics and Informatics
( ICSCI - 2012 )
Conference Dates: February 15 - 18, 2012
Venue: Dr. MCR HRD Institute, Government of Andhra Pradesh, India, Road No. 25, Jubilee Hills, Hyderabad – 500 033
http://www.hrdiap.gov.in ; Ph: +91-40-23548487; Fax:: 23548489; email: adm.ao@hrdiap.gov.in
Organized By: Pentagram Research Centre Pvt Limited
Corporate Address: 201, Venkat Homes, MIGH-59, Mehdipatnam, Hyderabad, Andhra Pradesh, India
Conference Secretariat Address: 1073, Road No. 44, Jubilee Hills, Hyderabad, Andhra Pradesh, India
Web Site: www.icsci.net ; Tel: +91-40-23553986; email: icscimail@yahoo.com
Mission: To Create A Knowledge Based Society
International Conference on Systemics, Cybernetics and Informatics is an event organized by Pentagram Research
Instructors
Dr. Andras Pellionisz
Dr. Anis Khimani
Dr. Bishwajit Nag
Dr. S. Chandrashekaran
Dr Kaiser Jamil
Dr. Karunagaran Devarajan
Dr Lakshmi Narasimhan
Dr Michael Coyle
Dr. Narasimhan Srinivasan
Dr. Raja Mugasimangalam
M. V. Ramanujam
S. Ramasubramanian
Dr. Srinivasan Ramachandran
On behalf of the ICSCI-2012 conference secretariat, I cordially welcome all the above scientists and invite them to conduct this workshop. I am sure that the participants would indeed derive maximum benefits from this great workshop.
Best wishes to one and all.
Prof. Dr. Rajiv Sharma
Department of Ocean Engineering
Indian Institute of Technology
Madras, Tamil Nadu
Co-Chair, ICSCI-2012
One Day Workshop on "Research in Life Sciences"
(0900 Hours to 1700 Hours, February 16, 2012)
Download Workshop
Brochure and Registration Form
Theme of the Workshop
The theme of the Workshop on Research In life Sciences is broad in nature but more or less centers around Bioinformatics, Genome Informatics, Cancer biology and Biotherapeutics. Speakers from across the globe will be conducting the workshop on Next generation sequencing, Data analysis of Next gen sequencing, Genome Analytics and Genome informatics. Furthermore emphasis will be placed on disease condition cancer, and detailed lectures will be presented on Cancer Biology, cancer genome analysis. Lectures and workshop will focus on Next gen sequencing technologies, Convergence of IT and Biology, Data analysis techniques, software in Next gen sequence analysis, and other latest Bioinformatics approaches to tackle the data deluge in due to advent of NGS technologies. Speakers will talk on research areas related to Fractal genomics, Fractal Anlaysis, Second generation and third generation sequencing technologies, Algorithm development, Biobanking and IT approaches, and as a add on Life sciences research in Biotherapeutics. Cancer as a focus, speakers will converge on this disease model and talk about Biology of cancer, Genomic approaches in Cancer, Clinical medicine, and sequencing for consumers. Modern technologies in IT and BT will converge, and address the present days need to tackle the issue of data deluge in a cottage style sequencing industry. Large scale Biology will be discussed, and detailed, and IT infrastructure service opportunities from India, and global perspective will be discussed. Finally IT infrastructure and cloud computing will be discussed for the Next gen sequence analysis, particular emphasis will be placed on the security issues in the public cloud. Private cloud will be advocated and importance of India for the services in this sector, and Indian role in sequencing industry, with global Indian in mind will be highlighted. Finally, a hands on session will be conducted in addition to Panel discussion which will be moderated and question answer session will be throwing light into the future for the next 10 years of Bioinformatics.
About the Instructors
Dr Andrias Pellionisz is a domain expert in Genome Informatics and he is a cross-disciplinary scientist and technologist. He has 45 years of experience in Informatics of Neural and Genomic Systems spanning Academia, Government and Silicon Valley Industry. Dr. Pellionisz played a leading role in the paradigm shift from Artificial Intelligence to Neural Nets, including the establishment of the International Neural Network Society. Today, his work is foundational to HoloGenomics, the integration of 100+ years of Genetics with 60+ years of Epigenetics. Dr. Pellionisz’ fractal approach to genome function is now corroborated by recently published findings about the fractal folding of DNA structure by Presidential Science Adviser Eric Lander. Dr. Pellionisz put forth the first theory of full genome (hologenome) recursive fractal iterative function, as the mathematical basis of genome regulation, presenting in Cold Spring Harbor Labs, 2009. Dr. Pellionisz was the first to provide a blueprint instruction for automated landing an F15 fighter on one wing with the Transputer parallel computer neural network. He subsequently participated in the government handover of Internet development to private industry. From 1994, he served as Chief Software Architect to several "dot com boom" Silicon Valley companies. Over the decades, Dr. Pellionisz successfully pioneered the geometrization of biology, first in neuroscience resulting in early industrial neural net applications and later in genomics, manifesting today in industrial applications for personal genomes.
Dr. Anis Khimani
is Sr. Manager, Strategic Marketing, at SeraCare Life Sciences, Inc.,
located in the Boston area, U.S.A. At SeraCare, he leads the Cellular
products and BioServices business portfolios and is responsible for
strategic initiatives to drive the success of these product lines. Prior to
SeraCare, Dr. Khimani held global product management positions at ESA
Biosciences (now part of Dionex, ThermoFisher Scientific) and Millipore
Corporation, both in the Boston area. Before joining Millipore, he had held
lead positions in Business Management, Business Development, Marketing and
Product Management in the Life Sciences division at Corning Incorporated.
Dr. Khimani was also Director of Marketing at Ventana Medical Systems, Inc.,
leading Marketing and Business Development efforts in Molecular Diagnostics
and Clinical research. His biotech career in the US began as a Research and
Applications Scientist at PerkinElmer Life Sciences, Inc. in Boston. With a
Doctorate in Virology from Indiana State, followed by a Postdoctorate in
Molecular Virology from Harvard Medical School and Dana-Farber Cancer
Institute in Boston, Dr. Khimani has had more than 15 years of research and
commercial experience in the biotech, biopharmaceutical, and molecular
diagnostics arena. He has authored and co-authored numerous publications,
chapters, reviews, and abstracts. He has been awarded numerous academic
honors and distinguished product management and marketing award, as well as
been invited to present talks at domestic and international conferences.
Dr. Bishwajit Nag is currently the Founder and CEO of RENOVEL DISCOVERIES INC. and NAG RESEARCH LABORATORIES INC. (NRL) where he is involved in developing new generation of technology based natural product drug discovery in diverse areas such as Diabetes, Obesity, Arthritis, Cancer and Neurological diseases. In 2011 he has launched India’s first natural product based drug discovery company “RENOVEL DISCOVERIES PVT LTD. in Bangalore, India with a subsidiary company in USA as RENOVEL DISCOVERIES INC. in San Francisco, CA. From 2002-2007 Dr. Nag was the Founder and CEO of BEXEL Pharmaceuticals Inc., CA, in partnership with Orchid Chemicals & Pharmaceuticals of Chennai, India. From 1996-2001 Dr. Nag served as the founder and chief scientific officer (CSO) at CALYX Therapeutics Inc., Hayward, CA, a technology based molecular drug discovery company for the treatment of Diabetes and Inflammation. Dr. Nag’s biotech business activity initiated at ANERGEN Inc. where he was the Director of R&D from 1988-1995, a NASDAQ-listed corporation (symbol: ANRG) later acquired by Corixa Corporation. At Anergen, he was involved in developing recombinant proteins based biologicals for the treatment of a number of autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), Type I diabetes and myasthenia gravis (MG) in collaboration with Novo-Nordisk, Ekzo-Nobel and Zymogenetics Inc (a subsidiary of Bristol-Myer Squib). Before joining Anergen Inc., Dr. Nag served as a senior scientist in the development of the recombinant tissue plasminogen activator (TPA) at Berlex Biosciences in collaboration with Abbott Laboratories. Dr. Nag received several international honors and awards during his career including American Medal of Honor in 2001, Cambridge International Scientist of the year in 2002, United States National Leadership award in 2003, ABI Hall of Fame award in 2005, George W. Bush Charter Presidential Award in 2007 and Congressional Merit Award in 2008. His extra curriculum activities include outdoor adventures such as cycling, rock-climbing, back-packing and hiking. Dr. Nag is actively involved in sponsoring U-23 cycling team “NRL-RACING TEAM” based in Berkeley California and GO-GET OUTDOOR TEAM based in San Francisco, CA. He is actively promoting two non-profit organizations: NAG FOUNDATION for assisting financially deprived students for education and MOTIVATION RESEARCH organization for realizing lifestyle potential for individuals.
Dr. S. Chandrashekaran is the Founder and Managing Director of Enzene Biosciences Pvt Ltd. This company's main focus is biotech and pharma fine reagents, diagnostic reagents, biopharma and recombinant industrial enzymes in addition to the several contract services in the area of molecular biology, immunology and drug discovery processes. During August 2002-2006 he was Research Scientist Biochemistry & Molecular Biology Division, AstraZeneca India Pvt. Ltd. From July 1999 to 2002, he was Group Leader, Bangalore Genei Pvt. Ltd., Banglore, INDIA. He was In-charge of a collaborative project with a U.S based biotech company, SurroMed. The project involves cloning, expression and refolding of several matured human interleukins, growth factors and subsequent evaluation of activity of these purified proteins in respective ELISA system. During 1994-1999, he was Joint Product development & Production Manager, Bangalore Genei Pvt.Ltd., Banglore, INDIA. He was engaged in research and product development of the company. The work involved development of several new reagents and tools for molecular biology and protein science. Involved in identification and characterization of newer restriction endonucleases and modifying enzymes then cloning them to hyper express in E. coli. He was Scientific Officer, Bangalore Genei Pvt. Ltd., Banglore, INDIA during 1990-1994. He was Group leader involved in purification of restriction endonucleases, modifying enzymes and immunological reagents. He was also in-charge of quality control department of the company for two years.
Dr Kaiser Jamil
is
Emeritus Research Scientist and Head, Genetics Department, ,Bhagwan Mahavir Medical Research Centre, AC Guards, Hyderabad-500004, A.P.
India. She is CSIR Emeritus Scientist and Head, Department of Genetics, Mahavir Hospital
and Research Centre, Hyderabad- 50004, A.P. India since 2001. She is Hon. Prof, and Director, School of Biotechnology –MGNIRSA, Hyderabad,
since 2003. She is also Dean, School of Life sciences, Jawaharlal Nehru Institute of Advanced
Studies (JNIAS) Centre for Biotechnology and Bioinformatics, Budha Bhawan
,6th Floor, Secunderabad-500003, A.P. India since 2009. She is former Research Director: Indo American Cancer Institute and Research
Centre, Banjara Hills, Hyderabad 500034, A.P.India during 2006-2008. She is
former Director Grade Scientist of IICT (Indian Institute of Chemical
Technology- CSIR) Hyderabad, 500007, A.P. India during 1981-2000. She is former Scientist of CCMB (Centre for Cellular and Molecular Biology- CSIR)
Hyderabad,-500007, A.P. India during 1971-1981. She was President Third World Organization of Women Scientists - TWOWS, Trieste, Italy
during 2005-2010. She has published more than 200 RESEARCH PAPERS in various peer reviewed journals
and AUTHORED TWO BOOKS Her research experience and activities include Biotechnology and Bioinformatics, Cancer Biology, Biomarkers, SNPs, Molecular Biology, Genetics, Electron Microscopy, Environmental and Medical Biotechnology, Studies on Metal ions in biological systems, Pharmacogenomics and Toxicogenomics.
Dr. Karunagaran is a Professor at the Department of Biotechnology, Indian Institute of Technology Madras, Chennai. He started his career as a lecturer in Biochemistry at the PSG college of Arts and Science, Coimbatore in 1979 and taught a number of BSc and MSc students for more than a decade.He has made significant contributions in the field of signal transduction, mediated by epidermal growth factor receptors (EGFRs) and their ligands implicated in the development of human cancer. A novel concept proposed by him (with Dr. Yosef Yarden from Israel) is that ErbB-2 (the second member of EGFR family) acts as the preferred heterodimeric partner of all the known members of the EGFR family, and at least, part of the transforming ability of an over expressed ErbB-2 is due to transactivation of growth factor signaling. Moderate expression of ErbB-2 is biased for heterodimerization with ErbB-3 and ErbB-4 receptors that bind neu differentiation factor. A monoclonal antibody against neu differentiation factor raised by him is being marketed by a U. S. Company. Dr. Karunagaran (with Dr. Mien-Chie Hung from Houston) discovered that adenoviral E1A suppressed the radiation-induced activation of Nuclear Factor kappa B (NF-κB), a transcription factor known to protect cells from cell death. This finding provides a plausible mechanism for the long-known susceptibility of cells to radiation-induced apoptosis in the presence of E1A. Dr. Karunagaran joined the Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram in December 1997. His laboratory studies are focused on cervical cancer, an important public health problem for adult women in India. Cervical cancer causes about 250,000 deaths annually worldwide, with women in the developing countries accounting for 80% of these deaths. Although human papilloma virus (HPV) infection is the major risk factor for cervical cancer, molecular alterations of tumor suppressor genes and/or oncogenes either associated with HPV infection or independent of it are necessary for the cervical cancer progression. Dr. Karunagaran has shown that the transcription factor, nuclear factor-kappa B (NF-κB) is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas during human cervical cancer progression (cited in text book “the biology of Cancer” on page 195, by Robert A. Weinberg, Garland Science http://www.garlandscience.com/textbooks/0815340788.asp). Many chemopreventive agents induce programmed cell death or apoptosis, a potent mechanism by which they eliminate preneoplastic or cancer cells. Curcumin, the yellow pigment derived from Curcuma longa, is a pharmacologically safe compound and possesses antioxidant, antiinflammatory and anticancer activities. Curcumin inhibits cell proliferation and induces apoptosis of several, but not all cancer cells. Dr. Karunagaran has proposed that differential over expression of certain antiapoptotic proteins may account for the failure of curcumin to induce apoptosis in some cancer cells. Results from his laboratory suggest antiapoptotic roles for NF-κB, Bcl-XL and heat shock proteins such as hsp70 in curcumin-induced apoptosis. His laboratory has identified that NF-κB can also regulate epidermal growth factor-induced apoptosis by a similar mechanism. Loss of transforming growth factor-β (TGF-β) sensitivity is observed in a wide variety of cancers including cervical cancer. His laboratory has reported a novel Smad 2 mutation in a human cervical tumor sample and loss of expression of Smad 2 and Smad 4 in different stages of cervical cancer progression and also the mutations of Smad 2 and Smad 4 in two of the six human cervical cancer cell lines analyzed revealing an important role for Smads in human cervical cancer for the first time. Two of his research publications are now recognized as classic citations (more than 400 citations each) and two more have more than 200 citations each and his ‘h-index’ has now increased to 23. For further details on current research interests, browse through the ongoing research projects.
Dr. V. Lakshmi Narasimhan is an object-oriented system/enterprise architect and cloud computing expert. His long track record of successes in large-scale distributed systems, web services and grid and cloud computing, is unique in the industry. He is well-experienced in technical training, having worked as professor, teaching courses at graduate, undergraduate and corporate levels. He has vast experience in needs and requirements analysis for cloud-based systems design, high-performance distributed-object system design, rapid cycle development, all types of testing, management, marketing and promotion, deployment of complex heterogeneous computer communication networks, with distributed, object-oriented, client-server, n-tier, and peer-to-peer computing environments, including cloud computing. He is the Chief Technology Officer of Pentagram Research Centre, the hosting company of this conference and he operates from New Bern, NC, USA.
Dr. Michael P. Coyle is Clinical Professor of Internal Medicine, Clinical Professor of Pediatrics, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA. He received his Bachelors of Science degree from Cleveland State University in Cleveland, Ohio. Subsequently, he received his M.D. degree from Wright State University in Dayton, Ohio. He proceeded with his specialty training in the combined specialty program of Internal Medicine and Pediatrics leading to his board eligibility and certification in both specialties. After this, he became a Fellow with the American Board of Pediatrics as well as a Fellow with the American College of Physicians. With regard to his practice of medicine, he has functioned in a variety of capacities. He has served in rural communities through the auspices of the National Health Service Corps, primarily in solo, as well as multi-specialty practices. He then joined the Brody School of Medicine at East Carolina University in Greenville, North Carolina. During his second year at this institution, he was asked to establish a multi-specialty, freestanding outpatient clinic and remained Medical Director of this clinic for 10 years. After this, he served as Chief Medical Officer for a federally qualified health center. Dr. Coyle presently practices clinical medicine as well as academic medicine in the areas of Internal Medicine and Pediatrics. He allows shadowing for college students and actively teaches medical students and residents at all levels. His primary interests include preventive medicine, cardiovascular health and sports medicine. Other interests include, but are not limited to, theoretical astrophysics (novice level)
Dr.S.Narasimhan, recipient of the Tamil Nadu Scientist award, obtained his Ph.D. in Chemistry, from the University of Madras. Subsequently he got associated with Prof. Herbert C.Brown, Nobel Laureate in Chemistry (1979) in Purdue University, West Lafayette, Indiana U.S.A. He returned to India and served as Senior Scientist in IDL Nitro Nobel Basic Research Institute, Bangalore and as Associate Director, Spic Science Foundation. He is currently the Founder Director of Asthagiri Herbal Research Foundation, an Institution achieved accreditation from DSIR, Ministry of Science and Technology, AYUSH, Ministry of Health and Family welfare and University of Madras under his guidance. Dr.Narasimhan has worked in interdisciplinary areas involving chemistry, natural products, biotechnology, entomology, microbiology and analytical . His research has resulted in the development of several crop protection formulations, health care products and novel lead molecules. His innovative technology on the application of pheromone technology to control sugarcane borers got him the coveted Tamil nadu Scientist Award and citation given by the Tamil Nadu State Council for Science and Technology. Dr.Narasimhan has been recognized as a guide for supervising researchers leading to Ph.D degree from the University of Madras, Sri Ramachandra Medical College and University, Bharathiar University and Bharath University. He has so far guided 22 Ph.Ds and 14 more are currently pursuing research in Chemistry and biotechnology. He has published more than 80 papers in National and International Journals, applied for 3 patents, conducted 3 international conferences. He has also established collaborations with Indian and Foreign Institutions for conducting research. A few of them are: Vel's College (Department of Biotechnology); Greenwhich University, UK; Nag Research Institute, Fremont ,USA. Many more collaborations are on the anvil. Dr.Narasimhan has generated a number of projects funded by DST,DBT,AYUSH,CSIR and a few private sponsors. The general area of research are chemistry, pheromone technology, herbal technology and biotechnology. Dr.Narasimhan has established a technology incubation center in the Asthagiri herbal research Foundation which caters to the guiding of a number of students for their projects and award of grant from Technopreneur under the TEPP scheme from CSIR/DST. One such project is the development of hydroponic device. Dr.Narasimhan is a well recognized and reputed Scientist and academician known for his dedicated work. He has been serving as a Member in the Advisory committees of several Institutions. Has been recognized as a Leader in the field of Pheromone technology and served as a Chairman of the committee for guiding Plant Protection department for pheromone registration. He also served as the Task Force Member of the Department of Biotechnology, Ministry of Science and Technology.
Dr. Raja Mugasimangalam (Founder and CEO Genotypic technology, Bangalore India) is a technocrat turned entrepreneur in the Genomics Business Since 1998, helping clients apply Sequencing, Bioinformatics and Microarray technologies in real life research projects. Prior to founding Genotypic Technology, he worked at Quark Biotech Inc (USA and Israel) developing methods for constructing Microarrays for studying drug toxicity in rat diabetes model. His received his Masters (1998) in Biotechnology and PhD (1994) in Biotechnology (Restriction modification systems and repair of DNA in E.coli) from Madurai Kamaraj University and worked as postdoctoral Scientist at Weizmann Institute of Science (Human Genome Project) , Israel and Sidney Kimmel Cancer Center (cloning of DNA acting proteins from virus and alteration in specificity of restriction enzymes), San Diego USA. Raja worked at Argonne National lab (Chicago USA) on developing novel methods for DNA sequencing for Human Genome Project. Currently at Genotypic, Raja collaborates with leading researchers, scientific institutions and pharma-biotech companies from all over the world. Genotypic is in the process of expanding into all the NGS sequencing technology platforms with the goal of ameliorating the wetlab and analysis process and using them in optimal combination for biological research in various domains. Simplifying the complex genomics technologies with an eye for “looking out for small changes that make big positive difference” is the main operations mantra.
M. V. Ramanujam (Ram) completed his MSc in Biochemistry and MS in Molecular Biology (USA) from New Mexico State University. He was a PhD Candidate at University of Kansas, and later joined Regeneron Pharmaceuticals Inc NY USA as Research Scientist. He was also with Biocon India Limited, University of Kiel, Tsukuba University, and Satyam Computers Limited. He held various positions in these institutions, and he was the Head of Molecular Biology at Bhat Biotech Limited. Currently he is Vice President at E Logic Technologies Pvt Limited with the BINET division. Ram has discovered a Procaryotic Transglutaminase from B subtilis cells in 1988 which is widely cited. His work is listed in the Sporulating: Webster's Timeline History, 1951-2007 by Icon Group Interntaional (Jun 6, 2009). Ram also invented a technology for Real time monitoring of ribozyme reactions by FRET. Ram was a wet Biologist working on Neurotrophic factors, and neurotrophins at Regeneron Pharmaceuticals Inc. He also specializes on RNase P and Hammerhead Ribozymes.His accomplishments include working on RNA-small molecule interactions, and Discovery projects. Ram was a Bioinformatician since 2000 and concentrates on the convergence of IT and BT, and has dlivered projects from India. Ram received widely cited honour for his Transglutaminase work and proteolysis work with Prof Dr Jim Hageman of New Mexico State University and has also worked with Prof Dr Peter Gegenheimer of University of Kansas. Ram was a research associate under Prof Dr Guido Krupp of Germany and Prof Dr Kaz Taira of Tsukuba University. Ram currently concentrates on Next Gen sequence data analysis and management on the public and private clouds., and on cloud computing. Ram’s current responsibility include P and L accountability, customer management, domain delivery and delivery of outsourced services. Ram leads a team at E Logic technologies, who are a pioneer in the space of Genome informatics in India and forayed recently in to cloud computing. Ram has been pioneering alliances and partnerships for E Logic Technologies, he has brought the Holgen technologies Alliance to E Logic technologies and collaborates on Genome Analytics with Holgen Technolgies Inc USA. Ram further has interest in Proteomics and Life sciences informatics which he wants to pursue in a Phases manner, as Genomics is the his current focus. Ram has been trained in Wet lab from New Mexico State University USA, University of Kansas USA, Kiel University Germany, Tsukuba University Japan and in Indian companies and foreign Biotech institutions. His Bioinformatics and Bio IT expertise stems from the fact that he was associated with first Bioinformatics company in India DSQ Biotech in 2000. He was also instrumental for Domain Molecular Biology at Satyam Bioinformatics.
S. Ramasubramanian has a rich experience of more than 28 Years in the field of Pharmaceutical Industries. He has 11 Years experience in International Pharma Marketing of Formulations of Generics and Branded Generics with good knowledge of various therapeutic groups and live International contacts. He has good knowledge of Bulk drugs with global contacts. He has 14 Years in Domestic Pharma Marketing with knowledge of antibiotics,antidiabetics,Cardiovasculars,antiallergics and Proton pump inhibitors. Now he is working as Head of Business Development with Chromous Biotech Pvt Ltd from Dec 2010. He is heading both the Global and National Marketing for molecular diagnostic products and is involved in business development in European,Asean,middle east,African,Central American and latin American markets.
Dr S Ramachandran received Ph.D. in Biochemistry with Plant Molecular Biology specialization, University of Idaho, Idaho 83843, USA in 1993. He did his M.Sc. in Biochemistry, University of Madras, Tamil Nadu, India in 1983. He completed his B.Sc. in Zoology, University of Madras, Tamil Nadu, India in 1981. At present, he is Chief Executive Officer in JOil Singapore Pte Ltd. He is also Director PT Jatropha Oil, Indonesia since August 2011, Director in PT Monfori, Indonesia, Director in Temasek LifeSciences Lab, Singapore since August 2002, He was with Joint lab, Institute of Genetics and Developmental Biology, Chinese Academy of sciences, Beijing, China as Principal Investigator during 2003-2008. He has Over 40 in international Journal publications to his credit.
Workshop fee:
Rs 1,000 /-
Benefits to the participants:
1. Exposure to advanced research topics in various specialized topics in life sciences (Learn from the leaders)
2. Certificate signed by all the instructors (A valuable document for academicians)
3. CD containing the lecture material (All in PDF format)
4. Complimentary lunch with the instructors (Interact briefly with them during lunch)
5. Complimentary high tea with the instructors (Interact briefly with them during tea break)
6. Rare opportunity to discuss with the instructors (Interact at length with them after workshop)
7. Discuss your research problems with the instructors
M. V. Ramanujam
Vice President, BINET, Elogic Technologies Pvt Limited
Workshop Co-ordinator
| Home | Contributed Papers | Students Papers | ICSCI-2004 | ICSCI-2005 | ICSCI-2006 | ICSCI-2007 | ICSCI-2008 | ICSCI-2009 | ICSCI-2010 | ICSCI2011 | ICSCI2012 |